Consensus Allogene Therapeutics, Inc.

Stocks

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq 06:00:00 18/09/26 am AEST			5-day change	1st Jan Change
1.730 ^USD	+2.37%		-1.70%	+26.28%

10/09	Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM
03/09	Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026	CI

Evolution of the Average Target: Allogene Therapeutics, Inc.

Evolution of the Target Price: Allogene Therapeutics, Inc.

Changes in Analyst Recommendations: Allogene Therapeutics, Inc.

2ffada23d9f67869151.sjCwA-SKBEAIXCXKNmmp879qhkHLjSI1dj0zvPI_nNc.23mEdI27fCRKJmqtRR_FwfEh_Haf_m1mIlReyLBuqaDgCIRMnN1ccnw3cA~81ab12490d22a4f3298af0a3d8f3081d

Analysts' recommendations: Allogene Therapeutics, Inc.

14/08	Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says	MT
16/04	JPMorgan Upgrades Allogene Therapeutics to Neutral From Underweight	MT
08/01	UBS Initiates Allogene Therapeutics at Buy With $8 Price Target	MT
10/10/25	JPMorgan Downgrades Allogene Therapeutics to Underweight From Neutral	MT
04/08/25	JPMorgan Downgrades Allogene Therapeutics to Neutral From Overweight	MT
07/07/25	RBC Cuts Price Target on Allogene Therapeutics to $9 From $10, Keeps Outperform, Speculative Risk	MT
15/05/25	Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating	MT
14/05/25	Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating	MT
09/11/24	Oppenheimer Adjusts Allogene Therapeutics Price Target to $10 From $11, Maintains Outperform Rating	MT
08/08/24	Truist Adjusts Allogene Therapeutics' PT to $14 From $17, Keeps Buy Rating	MT
08/08/24	Oppenheimer Adjusts Allogene Therapeutics Price Target to $11 From $13, Maintains Outperform Rating	MT
31/05/24	Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target	MT
21/05/24	Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	MT
16/05/24	HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating	MT
14/05/24	Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating	MT
14/05/24	B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating	MT
20/01/24	HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating	MT
06/01/24	B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating	MT
06/01/24	JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform	MT
09/12/23	Citigroup Starts Allogene Therapeutics With Buy Rating, $7 Price Target	MT
15/11/23	HC Wainwright Cuts Price Target on Allogene Therapeutics to $12 From $23, Keeps Buy Rating	MT
25/09/23	JPMorgan Adjusts Allogene Therapeutics Price Target to $9 From $11, Maintains Overweight Rating	MT
12/07/23	Truist Securities Lowers Allogene Therapeutics' Price Target to $18 From $20, Maintains Buy Rating	MT
07/07/23	RBC Lowers Allogene Therapeutics' Price Target to $12 From $15, Keeps Outperform Rating	MT
06/05/23	JMP Securities Adjusts Allogene Therapeutics' Price Target to $15 From $19, Keeps Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALLOGENE THERAPEUTICS, INC.					+432.54%
	WUXI APPTEC CO., LTD.					+18.61%
	ARGENX SE					+20.4%
	INSMED INCORPORATED					+62.79%
	BIONTECH SE					+23.92%
	GENMAB A/S					+10.98%
	PHARMAESSENTIA CORPORATION					+15.96%
	EXELIXIS, INC.					-5.45%
	SUMMIT THERAPEUTICS INC.					+68.17%
	MADRIGAL PHARMACEUTICALS, INC.					+28.16%
	Average					+67.61%
	Weighted average by Cap.					+26.06%